TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35441854
Drug: Local estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local estradiol (twice weekly estradiol cream from delivery through 3 months postpartum)
Study: 35441854
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (twice weekly from delivery through 3 months postpartum)
Study: 32013913
Drug: Intravitreal conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal conbercept (IVC) injection at the end of pars plana vitrectomy
Study: 32013913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IVC injection)
Study: 32013913
Drug: Intravitreal conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal conbercept (IVC) injection
Study: 34009790
Drug: Head and
Normalized name: Head and Shoulders
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head and neck cooling treatment applied at postinjury assessment visit and at 72 hours post-injury
Study: 34009790
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (short term brain rest)
Study: 34180719
Drug: MSCs transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCs transplantation therapy (3 × 10^6 cells/kg, intravenously) on treatment days 0, 3, and 6
Study: 34180719
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group 1 and Group 2)
Study: 34180719
Drug: MSCs transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCs transplantation therapy (Group 3)
Study: 32111302
Drug: 0.069 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.069 mg/kg 25-Hydroxycholecalciferol (25-OH-D3) in NRC vitamin premix
Study: 32111302
Drug: 0.069 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.069 mg/kg 25-Hydroxycholecalciferol (25-OH-D3) in standard nutrient density diet with NRC vitamin premix
Study: 35971137
Drug: 10 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sessions of symptom-specific CBT-VR plus treatment as usual
Study: 35971137
Drug: 10 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sessions of standard symptom-specific CBT for paranoid ideations (CBT) plus treatment as usual
Study: 35962688
Drug: Low-volume Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume Ringer's solution infusion
Study: 34842533
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy (KAD_SCL_01)
Study: 36432449
Drug: Two-year intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-year intervention based on the Mediterranean diet including group nutritional education, individualized dietary treatment, and physical activity program
Study: 34660639
Drug: Latent MTrPs
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latent MTrPs injection
Study: 34919104
Drug: Nutraceutical containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical containing 3 g d‐1 or 5 g d‐1 doses of 35% or 70% BG with 600 mg d‐1 of GCBE
Study: 34919104
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g - 70% BG
Study: 32007207
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg plus standard antiemetic therapy
Study: 32007207
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard antiemetic therapy
Study: 34974824
Drug: DoIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DoIT performed once weekly (DoIT-1, n=24)
Study: 34974824
Drug: DoIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DoIT performed twice weekly (DoIT-2, n=23)
Study: 34974824
Drug: DoIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DoIT performed thrice weekly (DoIT-3, n=21)
Study: 33396972
Drug: 3.2 g
Normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g bovine colostrum orally twice a day for 24 weeks
Study: 35279470
Drug: Metformin users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin users (327 patients with DM)
Study: 35279470
Drug: Non-metformin users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-metformin users (294 patients with DM)
Study: 33980057
Drug: Decision Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision Aid Tool (DAT) for LT4 dosage adjustment
Study: 33594986
Drug: Oral 200.000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 200.000 IU Cholecalciferol per month
Study: 35410145
Drug: Modified comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified comprehensive geriatric assessment and monthly standardized case conferencing
Study: 35524357
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) 60 IU/kg twice weekly for 52 weeks
Study: 34216524
Drug: Intensive-therapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive-therapy group
Study: 36818484
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (0.5 µg/kg)
Study: 39375952
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing
Study: 33212267
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with low-power laser, 660 nm, 40 mW, 120 J/cm2, 4.8 J, 120 s per point and methylene blue (0.005 %) as photosensitizer
Study: 33212267
Drug: Topical Acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Acyclovir (AC) 5%
Study: 33421649
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of HPV vaccine (Cervarix or Gardasil-9)
Study: 33421649
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV vaccine (Cervarix or Gardasil-9) given 6 months apart
Study: 33421649
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV vaccine (Cervarix or Gardasil-9)
Study: 32187166
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOACs), primarily Rivaroxaban and Apixaban
Study: 32187166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified (standard treatment with warfarin)
Study: 36242636
Drug: 5-ALA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA (20 mg/kg) administered orally or via a gastric tube prior to surgery
Study: 34182577
Drug: Parent-administered oral
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered oral stimulation (PIOMI)
Study: 34182577
Drug: Professional-administered oral
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional-administered oral stimulation (PIOMI)
Study: 33903280
Drug: High-dose intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intervention
Study: 33903280
Drug: Low-dose intervention
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intervention
Study: 32202965
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal treatment (ENDO)
Study: 33288629
Drug: Fixed-dose darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-dose darbepoetin (0.45 µg/kg every 4 weeks)
Study: 33288629
Drug: Titration-dose darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration-dose darbepoetin (based on hemoglobin levels)
Study: 35175572
Drug: Cimetidine as
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine as adjuvant therapy
Study: 35175572
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without cimetidine
Study: 33138061
Drug: 30 g/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/120 kcal whey-protein drink
Study: 33138061
Drug: 70 g/280
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g/280 kcal whey-protein drink
Study: 32676977
Drug: TRV250 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV250 (subcutaneous administration)
Study: 32676977
Drug: TRV250 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV250 (oral administration)
Study: 33589450
Drug: TKI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI plus local consolidative radiation therapy (LCRT)
Study: 37552354
Drug: 6-month adjuvant
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month adjuvant chemotherapy with S-1
Study: 37552354
Drug: 12-month adjuvant
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month adjuvant chemotherapy with S-1
Study: 37552354
Drug: 6-month adjuvant
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Study: 37552354
Drug: 12-month adjuvant
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Study: 33994406
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy targeting LDL-C <70 mg/dl
Study: 33994406
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy targeting LDL-C 100-120 mg/dl
Study: 34097646
Drug: Personalized support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized support at home (monthly home-based visits focusing on nutritional counseling and pregnancy management)
Study: 34949626
Drug: Optimised physiotherapist-led
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised physiotherapist-led treatment package including advice and education, exercise therapy, and orthotics.
Study: 34949626
Drug: Condition-specific advice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condition-specific advice, health-promotion advice, exercise types, exercise into 'acceptable' levels of pain, exercise dosage, and type of orthoses.
Study: 34949626
Drug: Electrotherapy, acupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrotherapy, acupuncture, and manual therapy were excluded from the treatment options.
Study: 35765796
Drug: Phyto corrective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyto corrective mask (once weekly), phyto corrective gel (twice daily), resveratrol antioxidant serum (at night)
Study: 35165099
Drug: Combination (Lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Lapatinib and Trastuzumab)
Study: 34051120
Drug: Home Biofeedback
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Biofeedback Therapy (HBT)
Study: 34051120
Drug: Office Biofeedback
Normalized name: Office First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office Biofeedback Therapy (OBT)
Study: 35311720
Drug: Bobath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath therapy with additional specific soft tissue mobilizations
Study: 33553040
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of traditional fermented food (Ash-Kardeh) daily in addition to the usual treatment
Study: 33553040
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment of diabetic patients
Study: 32967500
Drug: ATP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP group (androl, thalidomide, and PND capsule)
Study: 35483677
Drug: Buprenorphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2.5 μg/kg
Study: 35438672
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g potato protein
Study: 35438672
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g milk protein
Study: 33653909
Drug: Conventional Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oxygen Therapy via T-tube
Study: 34628372
Drug: Patient-Controlled Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Intravenous Analgesia (IVPCA)
Study: 32823218
Drug: Single parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single parenteral dose of 300,000 IU of vitamin D
Study: 32379661
Drug: Integrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative therapy (short-term psychodynamic psychotherapy & cognitive-behavioral therapy)
Study: 33795561
Drug: Abrocitinib 30
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abrocitinib 30 mg
Study: 33795561
Drug: Abrocitinib 10
Normalized name: abrocitinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 10 mg
Study: 36207050
Drug: 1.5×10^6 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5×10^6 IU of low-dose IL-2
Study: 35713352
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (DT) sessions using the Empathic Communication Coding System (ECCS-DT)
Study: 33130645
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment protocol including drugs affecting pathogenetic mechanisms of the disease.
Study: 33130645
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment protocol
Study: 34532749
Drug: Guanxin Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxin Danshen Dropping Pill (0.4 g, thrice daily) and Andrographis tablet (0.2 g, thrice daily) for 4 weeks
Study: 34532749
Drug: Guanxin Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxin Danshen Dropping Pill (0.4 g, thrice daily)
Study: 32196856
Drug: Intramuscular hyosine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hyosine n-butyl bromide (HBB) 40 mg (2 mL)
Study: 32196856
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of water for injection)
Study: 33522342
Drug: Pravastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (2 × 20 mg p.o) in addition to aspirin (80 mg p.o) and calcium (1 g p.o) from 14 to 20 weeks until delivery
Study: 33825498
Drug: Conventional-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CT (CDCT) (n = 1539 patients)
Study: 36004716
Drug: Probiotic Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Bacillus clausii UBBC‐07 (2×10^9 per 5 ml vial) taken daily twice for three months
Study: 33563473
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration during KT
Study: 34610332
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy in combination with surgery
Study: 32602373
Drug: Small needle-knife
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small needle-knife therapy (1 to 3 treatments over seven days)
Study: 32602373
Drug: Oral Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Celecoxib
Study: 32870471
Drug: Once-weekly dulaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dulaglutide 0.75 mg
Study: 33599688
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin
Study: 33599688
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy without carboplatin
Study: 33675133
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (poor prognostic pathologic factors; concurrent 56-Gy chemoradiotherapy with weekly cisplatin)
Study: 32214062
Drug: Task-based mirror
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-based mirror therapy (TBMT) for 25 minutes per day for 25 days
Study: 32214062
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (control group) for 25 minutes per day for 25 days
Study: 37477875
Drug: ChAd155-RSV high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd155-RSV high dose (5 × 10^10 viral particles)
Study: 36179066
Drug: UP165 (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP165 (corn leaf extract) 250 mg/day
Study: 36179066
Drug: UP165 (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP165 (corn leaf extract) 500 mg/day
Study: 35301135
Drug: Electronic sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic sleep positional therapy wearable device
Study: 35522187
Drug: Microfluidic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfluidic sperm preparation
Study: 32817311
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 400 μg oral supplementation once daily for a year
Study: 32683215
Drug: Hand Arm
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 g TOPICAL LIQUID [Hand Armor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand Arm Bimanual Intensive Therapy (HABIT)
Study: 32964537
Drug: Diuretic responsiveness
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic responsiveness
Study: 36209072
Drug: 1.0% phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% phentolamine mesylate ophthalmic solution (PMOS)
Study: 34290573
Drug: Bioresorbable vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresorbable vascular scaffold (BVS) + optimal medical therapy (OMT)
Study: 34863458
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus carboplatin chemotherapy
Study: 33612630
Drug: Caromma biscuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caromma biscuit (100 g/day for 4 weeks)
Study: 33612630
Drug: Temma biscuit
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temma biscuit (100 g/day for 4 weeks)
Study: 32966845
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose
Study: 34195469
Drug: Socio-spiritual intervention
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Socio-spiritual intervention consisting of four weekly face-to-face sessions focusing on spirituality, social support, and information needs
Study: 33534750
Drug: Radio frequency‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio frequency‐induced heat therapy (RFHT)
Study: 32135414
Drug: Chumlea's formulas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chumlea's formulas for whites (CC)
Study: 33378079
Drug: Implants without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants without peri-implantitis
Study: 33378079
Drug: Implants diagnosed
Normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants diagnosed with peri-implantitis
Study: 33378079
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors for buccal PISTD
Study: 32957034
Drug: Single-dose patellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose patellar tendon isometric exercise protocol
Study: 33385511
Drug: Ziziphus spinosa
Normalized name: Ziziphus jujuba var. spinosa seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziziphus spinosa (ZS) 2 g daily
Study: 32462542
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (1 µg/kg during a 10-min infusion)
Study: 32462542
Drug: Subcutaneous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dexmedetomidine (1 µg/kg during a 10-min infusion)
Study: 33964223
Drug: R21 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: R21 plus 25 μg MM (Group 1)
Study: 33964223
Drug: R21 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: R21 plus 50 μg MM (Group 2)
Study: 33544883
Drug: Tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg (after switching from ETN)
Study: 35975564
Drug: Ginseng (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (1 g/day)
Study: 33819509
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus rhamnosus GG administered for 3 months
Study: 32120316
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (two synbiotic capsules daily for 2 months)